{"schema_version":"1.0","type":"article","title":"這家公司臨床試驗失敗，反而被更加看好？","url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.md","lang":"zh-Hant","date":"2026-04-11","publish_at":"2026-04-11T10:30:00+08:00","updated_at":"2026-04-11","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"甲狀腺相關眼疾（thyroid eye disease, TED）這條賽道，最近又迎來一次很典型、也很殘酷的產業教育。","key_points":[],"facts":[],"sections":["III 期失利不是句點：當 batoclimab 倒下，IMVT-1402 還有機會挑戰 Tepezza 嗎？"],"references":[{"title":"[0]:  各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) :: Immunovant, Inc. (IMVT","source":"","date":"","url":""},{"title":"Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with…...","source":"","date":"","url":""},{"title":"www.immunovant.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Immunovant’s phase 3 trials of batoclimab fail to meet primary endpoints in thyroid eye disease","source":"Ophthalmology Times - Clinical Insights for Eye Specialists","date":"","url":""},{"title":"![Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 3）](images/dcard-03.png","source":"","date":"","url":""},{"title":"Immunovant, along with partner HanAll, will assess future plans for the development of batoclimab and provide an update at a future, unspecified date","source":"","date":"","url":""},{"title":"www.ophthalmologytimes.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 :: Immunovant, Inc. (IMVT","source":"","date":"","url":""},{"title":"NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal…...","source":"","date":"","url":""},{"title":"www.immunovant.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"https://www.biospace.com/press-releases/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted","source":"","date":"","url":"https://www.biospace.com/press-releases/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted"},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential :: Immunovant, Inc. (IMVT","source":"","date":"","url":""},{"title":"Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 IMVT-1402 was…...","source":"","date":"","url":""},{"title":"www.immunovant.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-01.webp"},{"alt":"Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-02.webp"},{"alt":"Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-11）。這家公司臨床試驗失敗，反而被更加看好？。https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-11-dcard-261276232-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}